BGLC BioNexus Gene Lab Corp
Services-Medical Laboratories · Nasdaq · SEC CIK 1737523 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.3%
TTM net income YoY-27.2%
TTM EPS YoY-130.3%
Revenue 3-yr CAGR-60.6%
Net income 3-yr CAGR—
Margins
Gross margin2.0%
Operating margin-461.1%
Net margin-463.1%
FCF margin20.5%
EBITDA margin-443.3%
Returns
ROE-40.7%
ROA-35.7%
ROIC (approx.)-37.8%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.01x
Current ratio3.74x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.05x
Accruals ratio-37.3%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.42M | $9.51M |
| Cost of revenue | $6.34M | $8.22M |
| Gross profit | $1.09M | $1.29M |
| R&D expense | $50,670 | $47,511 |
| SG&A expense | $1.54M | $1.83M |
| Operating income | -$2.97M | -$1.57M |
| Pretax income | -$2.98M | -$1.59M |
| Income tax | $0 | -$3,494 |
| Net income | -$2.98M | -$1.60M |
| EBITDA | -$2.85M | -$1.47M |
| EPS (diluted) | — | -0.09 |
| Weighted avg. shares (diluted) | — | 17.82M |
| Balance sheet | ||
| Cash & equivalents | $2.38M | $2.89M |
| Receivables | $505,885 | $1.38M |
| Inventory | $676,703 | $1.39M |
| Current assets | $5.37M | $7.43M |
| PP&E, net | $1.60M | $1.52M |
| Total assets | $9.25M | $10.43M |
| Current liabilities | $520,957 | $1.95M |
| Total liabilities | $637,856 | $2.11M |
| Shareholders' equity | $8.61M | $8.32M |
| Shares outstanding | 2.42M | 1.80M |
| Cash flow statement | ||
| Operating cash flow | -$1.84M | -$2.09M |
| Capital expenditure | $36,971 | $226,989 |
| Free cash flow | -$1.88M | -$2.32M |
| Investing cash flow | $944,751 | $418,202 |
| Financing cash flow | $298,841 | $3,975 |
| Depreciation & amortization | $111,873 | $104,160 |
| Stock-based compensation | $794,770 | $141,000 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.